NewsRoom Articles - Page 88 of 154 - PsychedelicNewsWire (PNW)

TuesdayAug 10, 2021 1:00 pm

Study Finds That Psilocybin May Change How the Human Brain Processes Tactile Sensations

Psilocybin is the active compound found in psychedelic mushrooms that induces psychological effects, mainly through the serotonin receptors. A study that was recently conducted has found a way to explain how psilocybin changes how the human brain processes mental representations and tactile sensations of an individual's body. While most of the underlying neurocognitive processes of these changes in an individual’s perception of self are unclear, it is known that the psychedelic substance causes alterations in body/self boundaries. Katrin Peller of the University of Zurich, who is the study's author, stated that research focused on psilocybin, among other psychedelic substances as…

MondayAug 09, 2021 2:30 pm

MDMA-Assisted Therapy May Be Effective in Treating PTSD in Couples

Post-traumatic stress disorder, commonly referred to as PTSD, is a mental health condition that is usually triggered by a petrifying event that one witnesses or experiences. The most common symptoms of the disorder include severe anxiety, upsetting dreams or nightmares, and flashbacks. Other symptoms include severe physical reactions or emotional distress in response to a situation that makes an individual recall the traumatic event or recurrent distressing memories of the event. Estimates show that post-traumatic stress disorder affects about seven million individuals in the United States. This disorder has been linked to various conditions, including anxiety and depression, as well…

FridayAug 06, 2021 1:00 pm

Oregon Board Concludes That Psilocybin Is Effective for Various Mental Health Diseases

A panel created in the state of Oregon under the psilocybin legalization measure that was approved by voters last year has submitted a report stating that psilocybin possesses significant medical benefits for various health conditions. The Oregon Psilocybin Advisory Board subcommittee reviewed nearly 600 studies on psilocybin and came to the conclusion that the psychedelic had demonstrated effectiveness in decreasing anxiety and depression, even in fatal conditions. The panel asserted that all the studies they reviewed used a clinically supervised setting. Their report, which was compiled after eight weeks of review, stated that psilocybin was found to increase spiritual well-being…

ThursdayAug 05, 2021 1:23 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present Flagship PFN Program at 2021 Canaccord Genuity Virtual Growth Conference

The company will present an overview of business operations and its pipeline, including the Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program for chronic pain and eating disorders The initial indication of lead drug candidate TRP-8802 is for fibromyalgia, but Tryp believes that psilocybin can be used for much more in the realm of unmet medical needs PFN’s development for its proprietary drug candidate, TRP-8803, focuses on increased efficacy, natural blood-brain barrier penetration, enhanced safety and toxicity profiles, reduced risk of abuse, and reduced risk of addiction Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a San Diego-based pharmaceuticals company, has joined the lineup of presenters…

ThursdayAug 05, 2021 1:15 pm

Massachusetts Legislators Consider Bill to Establish Task Force for Psychedelics

Last week, legislators in Massachusetts heard testimony about legislation that would establish a task force that would look into the consequences of legalizing psychedelic substances such as ayahuasca and psilocybin. The legislation was introduced by Rep. Mike Connolly, and while members of the Joint Judiciary Committee didn’t vote on the measure, Connolly made a case for the proposal, noting that emerging research proposed that entheogenic substances held significant therapeutic potential for various mental health conditions. He explained that serious issues, including addiction, anxiety, depression and post-traumatic stress disorder, were a challenge to address, which was why it was important to…

ThursdayAug 05, 2021 12:14 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Marks Milestone Moment as First Psychedelic Biotech to Trade on NYSE American Exchange

Company announces official approval for its common shares to be listed, traded on NYSE American Cybin will commit resources to reach the broadest investor audience, accelerate efforts to position Cybin as sector leader Companies that list on NYSE American can leverage a wide range of advantages In an historic move, Cybin (NEO: CYBN) (NYSE American: CYBN) will become the first psychedelic biotech company to trade on the NYSE American LLC stock exchange (https://ibn.fm/LQryy). Cybin received official approval for its common shares to be listed and traded on NYSE American last week, and the company anticipates that shares will start trading…

WednesdayAug 04, 2021 2:15 pm

More Adolescents Are Being Hospitalized During COVID-19 Due to Eating Disorders

A new study suggests that the number of teenagers who have been admitted to the hospital for serious illnesses caused by eating disorders has substantially grown during the coronavirus pandemic period. The research, which was published in the “Pediatrics” journal, found that in one hospital, admissions among adolescents who suffer from eating disorders had doubled during the first year of the COVID-19 pandemic. The center, Michigan Medicine, stated that while admissions linked to eating disorders in the years 2017 to 2019 averaged about 55 individuals annually, the center had recorded more than 120 hospitalizations in the pandemic’s first year, with…

TuesdayAug 03, 2021 1:45 pm

General Public’s Perception on Dangers of Psilocybin Mushrooms Align with Science

A new study suggests that the general public’s perception of the possible harms of psilocybin mushrooms doesn’t align with drug laws. The study found that magic mushrooms were considered to be less dangerous in comparison with tobacco, alcohol and other substances. The study was published in the “Journal of Psychopharmacology.” The study’s author, professor Carl Roberts from the department of psychology at the University of Liverpool, stated that he was greatly interested in how substances affected an individual’s behavior as well as their brain. He explained that he had been following research on the therapeutic potential of psychedelic substances such…

MondayAug 02, 2021 2:45 pm

Study Finds That LSD Affects Language Production in the Brain

A recent study published in the “Consciousness and Cognition” journal has found that language produced while an individual is under the influence of LSD shows decreased semantic coherence and increased entropy levels. In layman’s terms, this means that people were more likely to move from one topic to another and have more disorganized speech while under the influence of LSD. Entropy was developed by physicists to quantify lost energy in mechanical systems. However, researchers have found that this measure of randomness and uncertainty in a system can also be used to measure spontaneous activity in brain networks. Study author Enzo…

FridayJul 30, 2021 2:40 pm

Ketamine Treatment Study Conducted During Pandemic Highlights Antidepressant Properties

The coronavirus pandemic has affected many industries and economies around the world, in addition to affecting global physical health, with continuous disconnection and social isolation aggravating the mental health crisis further. It has also emphasized the need to find new ways to improve the treatment of mental health conditions, with one recent study reporting that ketamine held the potential to become an effective treatment for depression when administered during the pandemic. Ketamine is mainly used as an anesthetic but has also demonstrated that it can be used to treat depression. The study, which was reported in the “Psychiatry Research” journal,…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000